NSABP to Study Docetaxel in Operable Breast Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 23 No 5
Volume 23
Issue 5

COLLEGEVILLE, Penn--Rhône-Poulenc Rorer Inc. and the National Surgical Adjuvant Breast and Bowel Project (NSABP) have announced the initiation of a new clinical trial (B-27) utilizing docetaxel (Taxotere) in women with operable breast cancer.

COLLEGEVILLE, Penn--Rhône-Poulenc Rorer Inc. and the NationalSurgical Adjuvant Breast and Bowel Project (NSABP) have announcedthe initiation of a new clinical trial (B-27) utilizing docetaxel(Taxotere) in women with operable breast cancer.

Randomization will be into three groups: All groups will firstreceive four cycles of Adriamycin and cyclophosphamide (AC). Aftercompletion of AC, group I will have surgery to remove the localtumor; group II will receive four cycles of docetaxel, followedby surgery; group III will have surgery, followed by four cyclesof docetaxel. All groups will take tamoxifen (Nolvadex) for 5years.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.